リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「2-nitroimidazoles induce mitochondrial stress and ferroptosis in glioma stem cells residing in a hypoxic niche (本文)」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

2-nitroimidazoles induce mitochondrial stress and ferroptosis in glioma stem cells residing in a hypoxic niche (本文)

小池, 直義 慶應義塾大学

2020.12.14

概要

Under hypoxic conditions, nitroimidazoles can replace oxygen as electron acceptors, thereby enhancing the effects of radiation on malignant cells. These compounds also accumulate in hypoxic cells, where they can act as cytotoxins or imaging agents. However, whether these effects apply to cancer stem cells has not been sufficiently explored. Here we show that the 2-nitroimidazole doranidazole potentiates radiation-induced DNA damage in hypoxic glioma stem cells (GSCs) and confers a significant survival benefit in mice harboring GSC-derived tumors in radiotherapy settings. Furthermore, doranidazole and misonidazole, but not metronidazole, manifested radiation-independent cytotoxicity for hypoxic GSCs that was mediated by ferroptosis induced partially through blockade of mitochondrial complexes I and II and resultant metabolic alterations in oxidative stress responses. Doranidazole also limited the growth of GSC-derived subcutaneous tumors and that of tumors in orthotopic brain slices. Our results thus reveal the theranostic potential of 2-nitroimidazoles as ferroptosis inducers that enable targeting GSCs in their hypoxic niche.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1. Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11, 393–410 (2011).

2. Brown, J. M. & Wilson, W. R. Exploiting tumour hypoxia in cancer treatment.Nat. Rev. Cancer 4, 437–447 (2004).

3. Sharma, R. Nitroimidazole radiopharmaceuticals in hypoxia: Part II cytotoxicity and radiosensitization applications. Curr. Radiopharm. 4, 379–393 (2011).

4. Brown, J. M. The hypoxic cell: a target for selective cancer therapy–eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 59, 5863–5870 (1999).

5. Overgaard, J. Hypoxic radiosensitization: adored and ignored. J. Clin. Oncol.25, 4066–4074 (2007).

6. Wardman, P. Chemical radiosensitizers for use in radiotherapy. Clin. Oncol.19, 397–417 (2007).

7. Martin Brown, J., Yu, N. Y., Brown, D. M. & Lee, W. W. SR-2508: A 2- nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int. J. Rad. Oncol. Biol. Phys. 7, 695–703 (1981).

8. Rauth, A. M. Pharmacology and toxicology of sensitizers: mechanism studies.Int. J. Rad. Oncol. Biol. Phys. 10, 1293–1300 (1984).

9. Kizaka-Kondoh, S. & Konse-Nagasawa, H. Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia. Cancer Sci. 100, 1366–1373 (2009).

10. Rischin, D. et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of trans-Tasman radiation oncolog. J. Clin. Oncol. 24, 2098–2104 (2006).

11. Overgaard, J. et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5–85. Radiother. Oncol. 46, 135–146 (1998).

12. Eschwège, F. et al. Results of a European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas. Int. J. Rad. Oncol. Biol. Phys. 39, 275–281 (1997).

13. Grigsby, P. W. et al. Irradiation with or without misonidazole for patients with stages IIIb and IVa carcinoma of the cervix: final results of RTOG 80-05. Int. J. Rad. Oncol. Biol. Phys. 44, 513–517 (1999).

14. Lytle, N. K., Barber, A. G. & Reya, T. Stem cell fate in cancer growth, progression and therapy resistance. Nat. Rev. Cancer 18, 669–680 (2018).

15. Oya, N. et al. Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): radiosensitization efficiency and toxicity. Int. J. Rad. Oncol. Biol. Phys. 33, 119–127 (1995).

16. Kuwabara, M. et al. Radiation-chemical properties of the hypoxic cell radiosensitizer doranidazole (PR-350). J. Radiat. Res. 43, 77–77 (2002).

17. Yasui, H. et al. The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood–brain barrier disruption. BMC Cancer 13, 106 (2013).

18. Yahiro, T. et al. Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo. J. Radiat. Res. 46, 363–372 (2005).

19. Murata, R., Tsujitani, M. & Horsman, M. R. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole. Radiother. Oncol. 87, 331–338 (2008).

20. Karasawa, K. et al. Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study. Radiother. Oncol. 87, 326–330 (2008).

21. Nishimura, Y. et al. Phase I/II Trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung cancer (WJTOG-0002). Int. J. Rad. Oncol. Biol. Phys. 69, 786–792 (2007).

22. Colwell, N. et al. Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. Neuro-Oncol. 19, 887–896 (2017).

23. Sampetrean, O. et al. Invasion precedes tumor mass formation in a malignant brain tumor model of genetically modified neural stem cells. Neoplasia 13, 784–IN3 (2011).

24. Evans, S. M. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin. Cancer Res. 10, 8177–8184 (2004).

25. Bar, E. E., Lin, A., Mahairaki, V., Matsui, W. & Eberhart, C. G. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am. J. Pathol. 177, 1491–1502 (2010).

26. Bar, E. E. Glioblastoma, cancer stem cells and hypoxia: hypoxia regulates glioma stem cells. Brain Pathol. 21, 119–129 (2011).

27. Sakaue-Sawano, A. et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 132, 487–498 (2008).

28. Gao, M. & Jiang, X. To eat or not to eat—the metabolic flavor of ferroptosis.Curr. Opin. Cell Biol. 51, 58–64 (2018).

29. Leitsch, D., Kolarich, D., Wilson, I. B. H., Altmann, F. & Duchêne, M. Nitroimidazole action in Entamoeba histolytica: a central role for thioredoxin reductase. PLoS Biol. 5, e211 (2007).

30. Bogdan, A. R., Miyazawa, M., Hashimoto, K. & Tsuji, Y. Regulators of iron homeostasis: new players in metabolism, cell death, and disease. Trends Biochem. Sci. 41, 274–286 (2016).

31. Kwon, M.-Y., Park, E., Lee, S.-J. & Chung, S. W. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. Oncotarget 6, 24393–24403 (2015).

32. Skulachev, V. P. et al. An attempt to prevent senescence: a mitochondrial approach. Biochim. Biophys. Acta 1787, 437–461 (2009).

33. Skulachev, V. P. et al. Prevention of cardiolipin oxidation and fatty acid cycling as two antioxidant mechanisms of cationic derivatives of plastoquinone (SkQs). Biochim. Biophys. Acta 1797, 878–889 (2010).

34. Murphy, M. P. How mitochondria produce reactive oxygen species. Biochem.J. 417, 1–13 (2009).

35. Minami, N. et al. Organotypic brain explant culture as a drug evaluation system for malignant brain tumors. Cancer Med. 6, 2635–2645 (2017).

36. Adams, G. E. Hypoxia-mediated drugs for radiation and chemotherapy.Cancer 48, 696–707 (1981).

37. Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756–760 (2006).

38. Blanpain, C., Mohrin, M., Sotiropoulou, P. A. & Passegué, E. DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell 8, 16–29 (2011).

39. Urtasun, R. C., Coleman, C. N., Wasserman, T. H. & Phillips, T. L. Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward? Int. J. Rad. Oncol. Biol. Phys. 10, 1691–1696 (1984).

40. Fulton, D. S. et al. Misonidazole combined with hyperfractionation in the management of malignant glioma. Int. J. Rad. Oncol. Biol. Phys. 10, 1709–1712 (1984).

41. Deutsch, M. et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int. J. Rad. Oncol. Biol. Phys. 16, 1389–1396 (1989).

参考文献をもっと見る